09 July 2012

New Vaccines Based on Stomatostatin To Promote Weight Loss

Somatostatin is a 14-amino acid peptide that inhibits pituitary growth hormone release. It is also called somatotropin release-inhibiting factor (SRIF).

Peptide hormones are a class of peptides (short polymers of amino acid monomers linked by peptide bonds) that are secreted into the blood stream and have endocrine functions in living animals.

Somatostatin is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of thyroid stimutalting hormones, prolactin, insulin, and glucagon. It also acts as a neurotransmitter and neuromodulator.

Somatostatin was used to test the therapeutic effects of novel vaccines for reducing weight gain and increasing weight loss in diet induced obesity (DIO) model.

New vaccines promote weight loss

A new study, published in BioMed Central's open access journal, Journal of Animal Science and Biotechnology, assesses the effectiveness of two somatostatin vaccinations, JH17 and JH18, in reducing weight gain and increasing weight loss in mice.

Obesity and obesity-related disease is a growing health issue worldwide. Somatostatin, a peptide hormone, inhibits the action of growth hormone (GH) and insulin-like growth factor (IGF-1), both of which increase metabolism and result in weight loss. Vaccination with modified somatostatin causes the body to generate antibodies to somatostatin, effectively removing this inhibition without directly interfering with the growth hormones and subsequently increasing energy expenditure and weight loss.

Video: Targeted Drug, Adipotide, Melts Fat

Keith Haffer from Braasch Biotech LLC, tested the vaccinations in two groups of ten diet-induced obese male mice compared with a control group of ten mice which received saline injections. Mice in all groups had been fed a high fat diet for eight weeks prior to the study and continued to eat the same food for the duration of the six-week study. The vaccinations were administered twice - at the start of the study followed by a booster vaccination on day 22.

Four days after the first injection of modified somatostatin, the vaccinated mice had a 10% drop in body weight (not seen in the control mice). At the end of the study, results showed that both vaccines induced antibodies to somatostatin and significantly reduced body weight, sustaining a 10% lower body weight, without affecting normal levels of the growth hormone IGF-1, or insulin levels.

"This study demonstrates the possibility of treating obesity with vaccination", Keith explained. He continued, "Although further studies are necessary to discover the long term implications of these vaccines, treatment of human obesity with vaccination would provide physicians with a drug- and surgical- free option against the weight epidemic."


BioMed Central
Journal of Animal Science and Biotechnology
Braasch Biotech LLC
Effects of Novel Vaccines on Weight Loss in Diet-Induced-Obese (DIO) Mice
Anti-Diabetic Medicine Beneficial in Prevention of Long Term Maternal Obesity
Milk Ingredient, Nicotinamide Riboside, Protects Against Obesity
Study On Ephedrine And Weight Loss May Lead To Wearable Diet Vest That Burns Fat
Scientists Present Proof Green Coffee Beans Help in Fast Effective Weight Loss
Research Into Better Treatments For Obesity Induced Diabetes
Study Finds Second Generation Antipsychotics (SGAs) Activates MC4R Gene Trigerring Obesity and Weight Gain
Obesity Crisis Made Worse By Food Industry Policies and Practices
SFRP5 Molecule Identified As A Factor In Accumulating Fat In The Body
Ursolic Acid In Apple Peels Reduces Obesity And Associated Health Problems